week 3 drugs

?
  • Created by: hadar
  • Created on: 11-02-16 17:34
Temozolomide (alkylating agent)- mechanism of action
alkylate N7 or methylate O6 on guanine/ inhibit transmethylation of methyl groups of methionine into t-RNA/ produce peroxides as metabolites
1 of 10
Temozolomide (alkylating agent)- therapeutic affect
prevent cell cycle progression and inhibit DNA synthesis and cell division and cell growth through alkylation of the DNA and RNA/ tumour shrinkage, inhibit growth and inhibit matastasis
2 of 10
Carmustine (alkylating agent)- mechanism of action
more selective for crosslinking N7 alkylation
3 of 10
Carmustine (alkylating agent)- therapeutic affect
prevent cell cycle progression and inhibit DNA synthesis and cell division and cell growth through alkylation of the DNA and RNA/ tumour shrinkage, inhibit growth and inhibit matastasis
4 of 10
Lomustine (alkylating agent)- mechanism of action
more selective for crosslinking and methylation of 06
5 of 10
Lomustine (alkylating agent)- therapeutic affect
prevent cell cycle progression and inhibit DNA synthesis and cell division and cell growth through alkylation of the DNA and RNA/ tumour shrinkage, inhibit growth and inhibit matastasis
6 of 10
Procarbazine (nonclassic alkylating agent)- mechanism of action
more selective for crosslinking and t-RNA and hydrogen peroxide
7 of 10
Procarbazine (nonclassic alkylating agent)- therapeutic affect
prevent cell cycle progression and inhibit DNA synthesis and cell division and cell growth through alkylation of the DNA and RNA/ tumour shrinkage, inhibit growth and inhibit matastasis
8 of 10
BCG therapy- mechanism of action
binding to finbronectin-->urothelial activation--> inflammatory response-->CD4+, Th1 response--> secretion of cytokines and cheekiness
9 of 10
BCG therapy- therapeutic affect
→ antibodies kill the tumour cells either the compliment system or the activation of NK cells (antibody dependant cellular cytotoxcicity) Antibodies recruit NK cells to lyse them and producing cytotoxic granules.
10 of 10

Other cards in this set

Card 2

Front

prevent cell cycle progression and inhibit DNA synthesis and cell division and cell growth through alkylation of the DNA and RNA/ tumour shrinkage, inhibit growth and inhibit matastasis

Back

Temozolomide (alkylating agent)- therapeutic affect

Card 3

Front

more selective for crosslinking N7 alkylation

Back

Preview of the back of card 3

Card 4

Front

prevent cell cycle progression and inhibit DNA synthesis and cell division and cell growth through alkylation of the DNA and RNA/ tumour shrinkage, inhibit growth and inhibit matastasis

Back

Preview of the back of card 4

Card 5

Front

more selective for crosslinking and methylation of 06

Back

Preview of the back of card 5
View more cards

Comments

No comments have yet been made

Similar All resources:

See all All resources »See all pharma resources »